Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock (SCLM)
Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Västra Götaland
-
Gothenburg, Västra Götaland, Sweden, 41345
- Central intensivvårdsavdelning Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Septic shock.
- All patients will be resuscitated with fluids before the inclusion.
- Need of Norepinephrine infusion.
- Myocardial dysfunction in echocardiogram, either LVEF < 50% or Global Left Ventricular Systolic strain over -15%.
Exclusion Criteria:
- History of previous heart disease or pulmonary hypertension.
- Age < 18 years.
- Cardiac arrhythmia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Norepinephrine
Doser
|
Norepinephrine will be given to the patient due to septic shock.
After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
|
|
Active Comparator: Milrinone
Doser
|
Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Other Names:
|
|
Active Comparator: Levosimendan
Doser
|
Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in LV systolic strain
Time Frame: 1.5 hours
|
Changes in LV systolic function (global strain) will be assessed by 2D speckle tracking echocardiography
|
1.5 hours
|
|
Changes in RV systolic strain
Time Frame: 1.5 hours
|
Changes in RV systolic function (RV free wall strain) will be assessed by 2D speckle tracking echocardiography
|
1.5 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Sven-Erik Ricksten, Professor, Sahlgrenska Academy, dep of clinical science
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Shock, Septic
- Shock
- Cardiomyopathies
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Phosphodiesterase Inhibitors
- Sympathomimetics
- Vasoconstrictor Agents
- Phosphodiesterase 3 Inhibitors
- Norepinephrine
- Simendan
- Milrinone
Other Study ID Numbers
Other Study ID Numbers
- K050711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.